Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial 11 de novembro de 2021 DOWNLOAD DO ARTIGO - DR. CONRADO R. HOFFMANN FILHO